Transmission of human parvovirus B19 by coagulation factor concentrates.
The prevalence of antibody to human parvovirus B19 was determined in 86 children with congenital bleeding disorders. Forty-seven of 53 boys (89%) receiving non-heat-treated factor VIII or prothrombin complex concentrates were anti-B19 IgG positive compared with 38% of their age-matched controls and 48% of children treated with cryoprecipitate. Acute B19 virus infection occurred in 2 boys 3-4 weeks after they had received the same batch of commercial factor VIII concentrate. Of 11 susceptible children who had only received heat-treated National Health Service factor VIII concentrate (8Y), 1 acquired anti-B19 IgG. This suggests that 8Y heat-treated concentrate has a much reduced risk of transmitting B19 virus and, by implication, other less heat-stable viruses such as human immunodeficiency virus.
Williams
M D
MD
Haematology Department, Children's Hospital, Birmingham, UK.
Cohen
B J
BJ
Beddall
A C
AC
Pasi
K J
KJ
Mortimer
P P
PP
Hill
F G
FG
D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis; D000956:Antigens, Viral / Q000032:analysis; D001778:Blood Coagulation Disorders / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004340:Drug Contamination; D005169:Factor VIII / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D010322:Parvoviridae Infections / Q000453:epidemiology / Q000276:immunology / Q000635:transmission*
D000914:Antibodies, Viral; D000956:Antigens, Viral; D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D005169:Factor VIII